Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05773703 · ClinicalTrials.gov registry record · Early Phase 1
Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer
A Early Phase 1 study, sponsored by Ratio Therapeutics.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 23
- Enrollment target
NCT05773703: Completed Early Phase 1 study, sponsored by Ratio Therapeutics.
NCT05773703 is a Early Phase 1 study that has completed, run by Ratio Therapeutics. The registered enrollment target is 23 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05773703, a Early Phase 1 study, has completed, sponsored by Ratio Therapeutics.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
Exploratory study in adult males with metastatic prostate cancer intended to characterize the pharmacokinetics and biodistribution of PSMA-Targeted \[In-111\]-Labeled Trillium Compounds with and without the cytoprotective agent PTI-122. Up to 36 eligible subjects will be enrolled. Additional subjects may be enrolled if there is insufficient data for evaluation, for example if the original study subjects do not complete required imaging studies for reasons unrelated to adverse events. Up to four PSMA-Targeted \[In-111\]-Labeled Trillium Compounds will be evaluated. Each compound will be evaluated first without the cytoprotective agent, PTI-122, then the \[In-111\]-labeled Trillium Compound may be co-administered with PTI-122.
Primary Outcome
Tumor uptake measured on imaging
Interventions
- DRUG PSMA-Targeted [In-111]-Labeled Trillium Compound
- DRUG PTI-122
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2022-12-08 |
| Est. Completion | 2023-12-12 |
| Phase | Early Phase 1 |
What the finished NCT05773703 record still lists
NCT05773703 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 2 interventions - of which PSMA-Targeted [In-111]-Labeled Trillium Compound is the first listed.
NCT05773703 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05773703 about?
NCT05773703 is a clinical study titled "Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer". Exploratory study in adult males with metastatic prostate cancer intended to characterize the pharmacokinetics and biodistribution of PSMA-Targeted \[In-111\]-Labeled Trillium Compounds with and without the cytoprotective agent PTI-122. Up to 36 eligible subjects will be enrolled. Additional subject...
What is the current status of trial NCT05773703?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 23 participants. The study started on 2022-12-08. Estimated completion is 2023-12-12.
What interventions are being tested in trial NCT05773703?
The interventions under investigation include: PSMA-Targeted [In-111]-Labeled Trillium Compound (DRUG), PTI-122 (DRUG).
Who is sponsoring clinical trial NCT05773703?
This trial is sponsored by Ratio Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05773703's enrollment target sits among peer trials
23 1088th of 2000 higher than 898 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI